Leap Therapeutics Inc. buy melinda
Start price
15.10.18
/
50%
€55.92
Target price
22.01.19
€66.75
Performance (%)
-46.77%
End price
22.01.19
€29.77
Summary
This prediction ended on 22.01.19 with a price of €29.77. The BUY prediction by melinda for Leap Therapeutics Inc. performed very badly with a performance of -46.77%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Leap Therapeutics Inc. | 7.207% | 7.207% | -56.250% | -74.136% |
| iShares Core DAX® | 0.795% | 1.458% | 17.980% | 69.888% |
| iShares Nasdaq 100 | -3.088% | -0.762% | 3.169% | 101.814% |
| iShares Nikkei 225® | -0.952% | -2.268% | 12.208% | 45.300% |
| iShares S&P 500 | -1.393% | 0.199% | 1.698% | 63.763% |
Comments by melinda for this prediction
In the thread Leap Therapeutics Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 12/11 Publication de résultats
Engages in clinical stage immuno-oncology
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company.
It invests in great science and targeted research will rapidly translate molecules into high impact therapeutics.
The firm's pipeline is built upon identifying and developing translational-stage molecules in the areas of cell signaling and immuno-oncology.
The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company.
It invests in great science and targeted research will rapidly translate molecules into high impact therapeutics.
The firm's pipeline is built upon identifying and developing translational-stage molecules in the areas of cell signaling and immuno-oncology.
The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.
Nombre d'employés : 22 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for Leap Therapeutics Inc.
Leap Therapeutics Inc.
Start price
Target price
Perf. (%)
€16.40
27.09.20
27.09.20
€20.00
04.11.21
04.11.21
38.72%
05.11.21
05.11.21
Leap Therapeutics Inc.
Start price
Target price
Perf. (%)
€67.56
25.04.17
25.04.17
€70.81
05.05.17
05.05.17
5.74%
05.05.17
05.05.17